The University of Southampton
University of Southampton Institutional Repository

Efficacy and safety of pregabalin in generalised anxiety disorder: a critical review of the literature

Efficacy and safety of pregabalin in generalised anxiety disorder: a critical review of the literature
Efficacy and safety of pregabalin in generalised anxiety disorder: a critical review of the literature
The aim of this review is to summarise the literature on the efficacy and safety of pregabalin for the treatment of generalised anxiety disorder (GAD). Of 241 literature citations, 13 clinical trials were identified that were specifically designed to evaluate the efficacy and safety of pregabalin in GAD, including 11 randomised double-blind trials and two open-label studies. Pregabalin efficacy has been consistently demonstrated across the licensed dose
range of 150–600 mg/day. Efficacy has been reported for pregabalin monotherapy in elderly patients with GAD, patients with severe anxiety, and for adjunctive therapy when added to a selective serotonin reuptake inhibitor or serotonin-norepinephrine reuptake inhibitor in patients who have failed to respond to an initial course of antidepressant therapy. The two most common adverse events with pregabalin are somnolence and dizziness, both of
which appear to be dose-related. Pregabalin appears to have a low potential for causing withdrawal symptoms when long-term therapy is discontinued; however, tapering over the course of at least one week is recommended. A review of available evidence indicates that pregabalin is a well-tolerated and consistently effective treatment for GAD, with a unique mechanism of action that makes it a useful addition to the therapeutic armamentarium.
generalised anxiety disorder, pregabalin, efficacy, safety
0269-8811
1-14
Baldwin, David S.
1beaa192-0ef1-4914-897a-3a49fc2ed15e
den Boer, Johan
db36fd90-27d1-4b4e-98ed-8a4b76ebbc95
Lyndon, Gavin
df813a63-a30a-4f4b-93d9-98f50eebd5aa
Emir, Birol
b4fa165d-2501-402b-9976-f282de2b1b9c
Schweizer, Edward
27226e10-0b76-4113-b8f1-990c2a9ec959
Haswell, Hannah
84eb7bb9-eb4b-44fd-8174-0aec615dde91
Baldwin, David S.
1beaa192-0ef1-4914-897a-3a49fc2ed15e
den Boer, Johan
db36fd90-27d1-4b4e-98ed-8a4b76ebbc95
Lyndon, Gavin
df813a63-a30a-4f4b-93d9-98f50eebd5aa
Emir, Birol
b4fa165d-2501-402b-9976-f282de2b1b9c
Schweizer, Edward
27226e10-0b76-4113-b8f1-990c2a9ec959
Haswell, Hannah
84eb7bb9-eb4b-44fd-8174-0aec615dde91

Baldwin, David S., den Boer, Johan, Lyndon, Gavin, Emir, Birol, Schweizer, Edward and Haswell, Hannah (2015) Efficacy and safety of pregabalin in generalised anxiety disorder: a critical review of the literature. Journal of Psychopharmacology, 1-14. (doi:10.1177/0269881115598411). (PMID:26259772)

Record type: Article

Abstract

The aim of this review is to summarise the literature on the efficacy and safety of pregabalin for the treatment of generalised anxiety disorder (GAD). Of 241 literature citations, 13 clinical trials were identified that were specifically designed to evaluate the efficacy and safety of pregabalin in GAD, including 11 randomised double-blind trials and two open-label studies. Pregabalin efficacy has been consistently demonstrated across the licensed dose
range of 150–600 mg/day. Efficacy has been reported for pregabalin monotherapy in elderly patients with GAD, patients with severe anxiety, and for adjunctive therapy when added to a selective serotonin reuptake inhibitor or serotonin-norepinephrine reuptake inhibitor in patients who have failed to respond to an initial course of antidepressant therapy. The two most common adverse events with pregabalin are somnolence and dizziness, both of
which appear to be dose-related. Pregabalin appears to have a low potential for causing withdrawal symptoms when long-term therapy is discontinued; however, tapering over the course of at least one week is recommended. A review of available evidence indicates that pregabalin is a well-tolerated and consistently effective treatment for GAD, with a unique mechanism of action that makes it a useful addition to the therapeutic armamentarium.

Text
Baldwin-PGB-JoP2015.pdf - Other
Restricted to Repository staff only
Request a copy

More information

Accepted/In Press date: August 2015
e-pub ahead of print date: 10 August 2015
Keywords: generalised anxiety disorder, pregabalin, efficacy, safety
Organisations: Clinical & Experimental Sciences

Identifiers

Local EPrints ID: 380272
URI: https://eprints.soton.ac.uk/id/eprint/380272
ISSN: 0269-8811
PURE UUID: 6e6950e5-f7fe-41fb-8a16-de027765dfa8

Catalogue record

Date deposited: 08 Sep 2015 11:17
Last modified: 19 Jul 2019 20:37

Export record

Altmetrics

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of https://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×